Tags : QMF149

Novartis Reports Results of QMF149 in P-III PALLADIUM Study for

Tuba Khan December 6, 2019

Shots: The P-III PALLADIUM study involves assessing of QMF149 [indacaterol acetate + mometasone furoate (IND/MF)] vs mometasone furoate (MF) as monothx. in 2,216 asthma patients with medium or high dose […]readmore

Pharma

Novartis Reports Results of QMF149 (indacaterol acetate and mometasone furoate)

Tuba Khan May 30, 2019

Shots: The P-III QUARTZ study results involves assessing of QMF149 (150/80 Mu g) vs mometasone furoate (200 Mu g) delivered via Breezhaler & Twisthaler in 802 adult and adolescent patients […]readmore

Tags : QMF149

Novartis Reports Results of QMF149 in P-III PALLADIUM Study for

Novartis Reports Results of QMF149 (indacaterol acetate and mometasone furoate)

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : QMF149

Novartis Reports Results of QMF149 in P-III PALLADIUM Study for

﻿Novartis Reports Results of QMF149 (indacaterol acetate and mometasone furoate)

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company

Novartis Reports Results of QMF149 (indacaterol acetate and mometasone furoate)